← Back to Episodes
PODCAST

Your Gut, Your Supplements, Your Feelings — November 16

November 16, 2026·9:32·Episode 168

Quick Summary

This episode covers three fresh pieces of research: a Nature study on how gut bacteria shape HRT outcomes, a Guardian investigation into expensive menopause supplements that don't outperform cheap multivitamins, and new clinical research mapping distinct emotional patterns during the menopause transition. Nykki breaks down what all three mean in plain terms and takes a clear position on each.

Your Gut, Your Supplements, Your Feelings — November 16

0:000:00

Key Takeaways

  • ✦Your gut microbiome may affect how well hormone therapy works — a Nature-published study suggests bacteria in your gut and urinary tract play a role in how your body processes and responds to HRT.
  • ✦Menopause supplements costing over £400 a year (roughly $500 USD) performed no better than a basic multivitamin in a Guardian investigation — the premium price is not buying premium results.
  • ✦A new PubMed study found that women going through the menopause transition don't all struggle emotionally in the same way — researchers identified distinct groups with different emotional difficulty profiles, which matters for how support and treatment should be tailored.
  • ✦The idea that HRT either "works" or "doesn't work" is too simple — emerging research suggests individual biology, including gut health, may explain a lot of the variation in results.
  • ✦Emotional symptoms during perimenopause and menopause are real, varied, and clinically distinct — not just a side effect of sleep loss or a personality trait.

Episode Script

Thanks Toni. We've got a good one today — three stories, all published in the last few days, and each one genuinely worth your time.

Let's start with the Nature paper, because it's the kind of research that reframes a question a lot of women are already asking.

The question is: why does hormone therapy work so well for some women and barely seem to do anything for others? Same drug. Similar doses. Completely different results. For years, the working assumption was that it came down to things like age, timing — how far into menopause you are when you start — or just individual variation that medicine doesn't have a great explanation for yet.

This new research points somewhere different: your microbiome. Specifically, the bacteria living in your gut and in your urogenital tract, which is the area covering your bladder and vagina. The study, published in Nature, found that the makeup of those bacterial communities appears to influence how your body actually processes and responds to menopausal hormone therapy.

Here's why that's not as strange as it sounds. Your gut bacteria do a lot more than help you digest food. They're involved in metabolizing estrogen — breaking it down, processing it, deciding what gets reabsorbed into your bloodstream and what gets flushed out. There's actually a name for the part of the gut microbiome that handles this: the estrobolome. So in theory, two women could take identical HRT, but if their gut bacteria are processing estrogen differently, the amount that actually reaches their tissues and does something useful could be quite different.

The urogenital piece is newer and arguably even more interesting. The bacteria in that region seem to interact with local estrogen levels in ways that affect symptoms like vaginal dryness, urinary urgency, and recurring infections — all things that are very common in perimenopause and menopause, and all things that HRT is often used to address. If the local microbiome is working against you, you might not get the relief you're hoping for even if the HRT itself is fine.

Now — and this is important — this is mechanistic and observational research. It tells us there's a relationship. It does not yet tell us exactly how to use that information clinically. We're not at the point where your doctor orders a microbiome test before adjusting your HRT dose. That's not what this paper is saying, and I'd be skeptical of anyone selling that service right now.

But here is what I think this research actually does: it gives a credible biological reason why HRT isn't one-size-fits-all, and it opens the door to personalized hormone therapy that takes gut health into account. That's not science fiction. It's the direction the research is heading. And for women who've been told their HRT isn't working and have been left with a shrug — this at least offers a real mechanism worth investigating.

The kind of evidence your doctor would look at on a tool like OpenEvidence is moving in this direction too. Microbiome science has become a legitimate clinical topic, not just a wellness buzzword. This paper helps anchor it there.


From your gut bacteria to your supplement cabinet. A Guardian investigation published this week looked at menopause supplements — the kind that are specifically marketed for symptoms like hot flashes, brain fog, mood swings, and low energy — and found that products costing over £400 a year, which is somewhere in the range of $500 US dollars, performed no better than a basic multivitamin you could pick up for a few pounds.

I am not surprised. I want to say that clearly. This is not a shocking finding — it's a confirming one. The supplement industry targeting women in perimenopause and menopause has been riding a wave of genuine need and genuine frustration. Women are struggling. They feel dismissed by their doctors. They're looking for something that helps. And into that gap walks a beautifully packaged product with a lot of words on the label — ashwagandha, black cohosh, evening primrose, magnesium, B vitamins — often bundled together at a price that implies it must be doing something.

The business model works because desperation is real and because supplements in most markets are not held to the same evidence standard as medications. You don't have to prove your product works before you sell it. You just have to not make specific disease claims. So these brands say things like "supports hormonal balance" or "promotes calm" and that's legally fine even if the evidence for those claims is thin to nonexistent.

The Guardian's finding aligns with what the research has been saying for a while. Black cohosh has decades of studies behind it and the results are genuinely mixed — some trials show modest benefit for hot flashes, others show no effect. Evening primrose, red clover, maca — same story. Small studies, inconsistent results, nothing that holds up cleanly when you run a large rigorous trial.

What actually galls me is the price. Charging £400 a year — again, roughly $500 — for something that isn't outperforming a cheap multivitamin is not a wellness product. It's a margin. If a supplement genuinely helped, I'd want women to know. The issue isn't "supplements bad." The issue is that the evidence doesn't support charging a premium for most of what's on the market, and the marketing is designed to make you feel like it does.

If you're taking something and you feel it helps — pay attention to that. Track your symptoms. See if it's consistent. But if you're paying $40, $50 a month for a "menopause formula" because an ad convinced you it was going to change things, this is worth knowing: the evidence says probably not.


The third item is a PubMed study published just yesterday, and it goes somewhere the show hasn't spent a lot of time recently: emotional symptoms during the menopause transition.

The study used something called latent profile analysis — which sounds complicated but is essentially a statistical method for finding natural groups within a population. Instead of asking "how bad are your emotional symptoms on average," it asks: "are there distinct types of people, with distinct patterns of difficulty?" It turned out the answer is yes. The researchers identified several different profiles — groups of women who struggled with emotional regulation in noticeably different ways during perimenopause and menopause.

Some women in the study had broad difficulty: trouble managing emotions across the board, more impulsivity, more emotional reactivity. Others had a more specific pattern — they could manage emotions okay in the moment but struggled to tolerate distress when it lasted a while. And others scored relatively low across all the difficulty measures, meaning emotional regulation wasn't a major area of struggle for them even during the transition.

This matters because "emotional symptoms during menopause" tends to get flattened into a single narrative. You're either moody or you're not. You're anxious or you're fine. This research says the reality is more varied than that, and importantly, that the variation is structured — it's not random. Different profiles probably call for different kinds of support. The woman who's struggling with broad emotional reactivity might need something different than the woman whose main issue is not being able to tolerate sustained distress.

The study was published by Brandão and colleagues just this month, so it's fresh. It's also a relatively new application of this kind of analysis to menopause specifically, which makes it worth watching. If this line of research holds up, it could move the conversation from "menopause causes mood problems" — which is blunt and not that useful — toward something more like "here are distinct emotional patterns, and here's how to think about supporting each one." That's a meaningful shift in how clinicians could approach this.

Emotional symptoms during the menopause transition are real, they're clinically significant, and they are not just a side effect of bad sleep or a personality trait. This study adds nuance to that — and nuance is what women in this space actually need.


Sources curated automatically by the Hot Flasher pipeline.

Hot Flasher provides informational content only and does not constitute medical advice. Always consult a qualified healthcare provider for medical concerns.